Immune checkpoint inhibitors (ICIs) are known to achieve sufficient receptor occupancy at doses much lower than standard approved regimens, suggesting that reduced dosing may still maintain therapeutic efficacy. To explore this further, a study evaluated whether ultra-low-dose Nivolumab could retain clinical effectiveness in 500 patients with advanced solid tumors. The study found that ultra-low-dose Nivolumab significantly improved overall survival compared to chemotherapy (5.88 vs 4.70 months; hazard ratio (HR) 0.80), with higher one-year survival rates (27.3% vs 16.9%).
Progression-free survival was similar between groups, while severe treatment-related adverse events were less frequent with ultra-low-dose nivolumab (42.5% vs 60.8%). Additionally, quality of life was significantly better in the nivolumab group. These findings suggest that ultra-low-dose Nivolumab improves overall…
